Skip to main content
MRKR logo

MRKR · Marker Therapeutics, Inc.

Track MRKR — free
$1.09 -0.23 (-17.42%) At close · Nov 20
Market Cap
$18.17M
Shares
16.67M
Volume · Nov 20 1.97M Avg daily vol (3M) 703.97K

Price & Indicators

 

Key stats

Close
$1.09
Fri 20 Nov
Open
$1.34
Fri 20 Nov
Average volume, 30 days
1.4M
shares a session
Short interest
176K
1.1% of shares · 1.0 days to cover
Day range
$1.09$1.45
Open $1.34 Close $1.09
52-week closing range
$0.83$2.19
Close $1.09 50.2% under the high
Short volume, last session
36%
Last earnings
Nov 10, 2021
Latest filing
10-Q · Nov 16
Price history
Jan 2020 to Nov 2026

Up next

call held May 12, 2021

Latest documents

2026
Nov 19
Current report 8-K
$16.2 million CPRIT grant to advance MT-601 Phase 2 study

Marker Therapeutics was awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas to support its lead MAR-T therapy, MT-601, in the planned Phase 2 APOLLO study.

Other events
2 source passages
the Company has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT) The grant will be used to support the advancement of the Company’s lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in the planned Phase 2 APOLLO study. Open the document at this passage
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss narrows to $6.8 million; runway into Q2 2027

Marker Therapeutics' nine-month net loss narrowed to $6.8 million from $10.5 million, as research and development expenses fell 33%. The company cites substantial doubt about going concern and anticipates funding operations into the second quarter of 2027.

Net loss $1.84M Diluted EPS -$0.10
Read from the MD&A section
6 source passages
The decrease in our net loss during the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 was primarily due to cost decreases in our research and development activities. Research and development expenses decreased by 33% to $6.5 million for the nine months ended September 30, 2026, compared to $9.7 million for the nine months ended September 30, 2025. The use of cash primarily related to our net loss of $6.8 million and a $1.3 million decrease from changes in assets and liabilities, offset by $0.6 million of non-cash stock-based compensation. The use of cash primarily related to our net loss of $10.5 million, offset by $0.4 million of non-cash stock-based compensation. These factors raise substantial doubt regarding our ability to continue as a going concern. we anticipate that we will be able to fund our operating expenses and capital expenditure requirements into the second quarter of 2027, assuming no additional grant funds are received, either from new grants or from existing awarded grants. Open the document at this passage
Oct 19
Current report 8-K
FDA awards $2.6 million grant for MT-601 pancreatic cancer study

Marker Therapeutics was awarded $2.6 million by the FDA to fund a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer. Clinical initiation is anticipated in the first quarter of 2027.

Other events
3 source passages
Today, Marker announced that the Company has been awarded $2.6 million from the U.S. Food and Drug Administration (FDA) through its Orphan Products Clinical Trials grants program. The funding will support a Phase 1 clinical study evaluating the Company’s lead investigational MAR-T cell therapy, MT-601, in patients with locally advanced unresectable pancreatic cancer. We anticipate clinical initiation of our study in pancreatic cancer in the first quarter of 2027 Open the document at this passage
May 15
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $751.69K ▲ 115.3% Net loss $3.18M Diluted EPS -$0.16
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.95M
Trailing 12 months
Net income (TTM)
−$8.55M
Trailing 12 months
Revenue growth YoY
+115.3%
Year over year
Operating margin
-363.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.3%
Year over year · more shares
Price change (1Y)
+10.1%
Trailing year
Short interest
1.1%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg +5%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 19%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +14%
trailing
6-month return −23%
trailing
YTD return −27%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.06% of shares out · ▲ +61.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
36 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +34%
Y/Y
Free cash flow $-12.4M
Balance sheet $16.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 101%
annualized · 1-yr
Max drawdown −62%
past year
ATR 15.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 14, 2023
Reduction of Marker’s operating expenses · annually $11M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
+5% Bullish
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
19% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.06% of shares out · ▲ +61.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
36 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 19% Range high $2
vs 200-day avg -16% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MRKR
Marker Therapeutics, Inc.
this stock
$18.17M -26.8% -100.0% — 1.1%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
36
% held
23.4%
Net QoQ
-74.1K sh
Top holder
NEA Management Company, L…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
176.1K
Days to cover
1.0d
Change
+67.0K sh
View
Short Volume
Short vol %
36%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
85
Value
$81
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
73.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-12.2M
EPS diluted
$-0.79
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 19, 2026
This year
13

Marker Therapeutics was awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas to support its lead MAR-T therapy, MT-601, in the planned Phase 2 APOLLO study.

View
Exempt Offerings
Offering
$16.1M
Filed
Dec 30, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2021
View
Investor Relations
Latest news
Marker Therapeutics Awarded $16.2…
Published
Nov 19, 2026
View

Performance

5D 20D 120D MTD YTD
MRKR +25.3% +13.5% -23.2% +11.2% -26.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +33.9% +22.8% -14.1% +19.9% -28.0%
Key facts CIK 1094038 CUSIP 57055L206 13F (30d) 51 filings 34 filers Visit website Investor relations